Endocrine therapy for the treatment of postmenopausal women with breast cancer

BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.

(2010) HT Mouridsen et al.   CANCER RESEARCH

Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8.

(2010) R Jakesz et al.   CANCER RESEARCH

Circulating Tumor Cells in Breast Cancer: Fiction or Reality?

(2008) Massimo Cristofanilli et al.   JOURNAL OF CLINICAL ONCOLOGY

Letrozole Suppresses Plasma Estradiol and Estrone Sulphate More Completely Than Anastrozole in Postmenopausal Women With Breast Cancer

(2008) J. Michael Dixon et al.   JOURNAL OF CLINICAL ONCOLOGY

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY

Tamoxifen Chemoprevention Treatment and Time to First Diagnosis of Estrogen Receptor-Negative Breast Cancer

(2008) Y. Shen et al.   JNCI-Journal of the National Cancer Institute

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY

Intratumoral estrogen production in breast carcinoma: significance of aromatase

(2008) Takashi Suzuki et al.   Breast Cancer